Kestra Medical Technologies posts 60% revenue growth and raises 2027 guidance, fueled by strong WCD market penetration and improved in-network patient mix.
Kestra Medical Technologies reported strong Q1 2027 results with 60% revenue growth, raised full-year guidance, and expanding margins, indicating bullish momentum.
Kestra Medical Technologies reported a 60% year-over-year revenue surge in Q1 2027, driven by market share gains and an expanding in-network patient base. Management raised full-year revenue guidance to $141 million and lifted long-term gross margin targets to the mid-70% range, citing operational efficiencies and favorable payer dynamics.
Growth is fueled by competitive share gains, market expansion, a higher mix of in-network patients, and favorable payer coverage for non-ischemic patients.
The company is leveraging AI to automate administrative tasks and scaling transaction volumes without proportional headcount increases, while focusing on increasing fittings per sales representative.